Literature DB >> 12409831

Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection.

Hiroki Yamaue1, Masaji Tani, Hironobu Onishi, Hiroyuki Kinoshita, Mikihito Nakamori, Shozo Yokoyama, Makoto Iwahashi, Kazuhisa Uchiyama.   

Abstract

INTRODUCTION AND AIMS: The survival of pancreatic cancer patients with portal vein resection is extremely poor due to the high incidence of liver metastasis. The occurrence of liver metastasis is decreased by locoregional arterial infusion after pancreatic surgery. Chemosensitivity tests can provide the basis for individualized chemotherapy in each patient and predict the clinical response. Therefore, the current study was designed to clarify whether locoregional chemotherapy based on the results of chemosensitivity tests has the clinical effects of preventing liver metastasis and improving survival for patients with portal vein resection.
METHODOLOGY: The resected specimens from 40 of 47 patients with resection of pancreatic cancer were assessed for chemosensitivity to various anticancer drugs. Fourteen patients underwent portal vein resection due to direct invasion, and nine of these patients received intra-arterial adjuvant chemotherapy on the basis of the results of MTT assay to prevent liver metastasis. The remaining five patients received no chemotherapy.
RESULTS: None of the patients who received intra-arterial chemotherapy had liver metastasis, and this group of patients had improved survival. The mean survival of patients with intra-arterial chemotherapy was significantly longer than that of patients without chemotherapy (25.6 months with chemotherapy versus 9.4 months without chemotherapy).
CONCLUSION: A pilot study of postoperative intra-arterial chemotherapy showed the reduction of liver metastasis and improvement of survival among pancreatic cancer patients with portal vein resection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409831     DOI: 10.1097/00006676-200211000-00008

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  13 in total

1.  Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma.

Authors:  Kwang Yeol Paik; Seong Ho Choi; Jin Seok Heo; Dong Wook Choi
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

2.  The evaluation of duct-to-mucosal pancreaticojejunostomy in pancreaticoduodenectomy.

Authors:  Masaji Tani; Hironobu Onishi; Hiroyuki Kinoshita; Manabu Kawai; Masaki Ueno; Takashi Hama; Kazuhisa Uchiyama; Hiroki Yamaue
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

3.  Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.

Authors:  Masaji Tani; Manabu Kawai; Motoki Miyazawa; Seiko Hirono; Shinomi Ina; Ryohei Nishioka; Yoichi Fujita; Kazuhisa Uchiyama; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2008-03-15       Impact factor: 3.445

Review 4.  No-touch isolation techniques for pancreatic cancer.

Authors:  Tamotsu Kuroki; Susumu Eguchi
Journal:  Surg Today       Date:  2016-03-01       Impact factor: 2.549

5.  Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.

Authors:  Kentaro Maejima; Akira Tokunaga; Teruo Kiyama; Hitoshi Kanno; Hideki Bou; Masanori Watanabe; Hideyuki Suzuki; Eiji Uchida
Journal:  Gastric Cancer       Date:  2010-12-03       Impact factor: 7.370

6.  Complications with reconstruction procedures in pylorus-preserving pancreaticoduodenectomy.

Authors:  Masaji Tani; Manabu Kawai; Hiroshi Terasawa; Masaki Ueno; Takashi Hama; Seiko Hirono; Shinomi Ina; Kazuhisa Uchiyama; Hiroki Yamaue
Journal:  World J Surg       Date:  2005-07       Impact factor: 3.352

7.  miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.

Authors:  Wei Zhu; DanXia Zhu; Shiqiang Lu; Tongshan Wang; Jian Wang; Binghua Jiang; Yongqian Shu; Ping Liu
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

8.  Pylorus-preserving pancreaticoduodenectomy versus conventional pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Masaji Tani; Manabu Kawai; Seiko Hirono; Shinomi Ina; Motoki Miyazawa; Yoichi Fujita; Kazuhisa Uchiyama; Hiroki Yamaue
Journal:  Surg Today       Date:  2009-03-12       Impact factor: 2.549

9.  Adjuvant treatment.

Authors:  Asma Sultana; John Neoptolemos; Paula Ghaneh
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

10.  miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1.

Authors:  Li Zhou; Tianzhu Qiu; Jing Xu; Tongshan Wang; Jian Wang; Xin Zhou; Zebo Huang; Wei Zhu; Yongqian Shu; Ping Liu
Journal:  Pathol Oncol Res       Date:  2013-05-03       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.